Krystal Biotech, Inc. (KRYS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1245865,
    "name": "Krystal Biotech, Inc.",
    "stock_name": "Krystal Biotech, Inc.",
    "full_name": "Krystal Biotech, Inc.",
    "name_url": "stocks-analysis/krystal-biotech-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "221.96",
    "chg": 6.9,
    "chgp": "3.21%",
    "dir": 1,
    "prev_price": "215.06",
    "mcapval": "4,202.52",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US5011471027",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "812.69 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/krystal-biotech-inc-1245865-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Krystal Biotech Adjusts Valuation Amid Strong Financial Performance and Growth Indicators",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/krystal-biotech-receives-upgrade-to-strong-buy-following-valuation-improvement-3690051",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/KrystalBiotechI_mojoScore_3690051.png",
        "date": "2025-11-11 16:37:05",
        "description": "Krystal Biotech, Inc. has recently experienced a revision in its evaluation, moving to a fair valuation grade. The company showcases strong financial metrics, including a P/E ratio of 27 and a PEG ratio of 0.25, alongside impressive returns on capital and equity, reflecting effective resource management and consistent growth."
      },
      {
        "title": "Is Krystal Biotech, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-krystal-biotech-inc-overvalued-or-undervalued-3689276",
        "imagepath": "",
        "date": "2025-11-11 11:33:51",
        "description": "As of 7 November 2025, the valuation grade for Krystal Biotech, Inc. moved from expensive to fair. This suggests that the stock is currently fairly valued. Key valuation ratios include a P/E ratio of 27, an EV to EBITDA ratio of 23.83, and a PEG ratio of 0.25, indicating a strong growth potential relative to its price.\n\nIn comparison to its peers, Krystal Biotech's P/E ratio is higher than that of Halozyme Therapeutics, Inc., which has a P/E of 15.92, and significantly above Elanco Animal Health, Inc. at 19.25. Despite this, the company has demonstrated robust performance with a year-to-date return of 27.36%, significantly outpacing the S&P 500's return of 14.40% over the same period, reinforcing the notion that the stock is positioned well in the market...."
      },
      {
        "title": "Is Krystal Biotech, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-krystal-biotech-inc-overvalued-or-undervalued-3683187",
        "imagepath": "",
        "date": "2025-11-09 11:09:12",
        "description": "As of 7 November 2025, Krystal Biotech, Inc. has moved from an expensive to a fair valuation grade. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 27, a Price to Book Value of 4.02, and an EV to EBITDA ratio of 23.83. In comparison to its peers, Krystal's P/E ratio is higher than Halozyme Therapeutics, Inc. at 15.92 and Elanco Animal Health, Inc. at 19.25, indicating a premium valuation relative to these companies.\n\nThe PEG ratio of 0.25 suggests that the stock may be undervalued in terms of its growth prospects, especially when compared to the industry average. Additionally, Krystal Biotech has delivered strong returns, outperforming the S&P 500 with a year-to-date return of 26.34% compared to the index's 14.40%. Overall, the valuation metrics and strong performance suggest that Krystal Biotech is fairly valued at this time...."
      },
      {
        "title": "Krystal Biotech Hits New 52-Week High of $212.98, Showcasing Strong Growth",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/krystal-biotech-hits-new-52-week-high-of-21298-showcasing-strong-growth-3674064",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/KrystalBiotechI_priceRelatedfactors_3674064.png",
        "date": "2025-11-05 16:51:53",
        "description": "Krystal Biotech, Inc. has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. The company has a market capitalization of USD 4,203 million, a P/E ratio of 27.00, and has reported significant growth in net profit and operating cash flow over recent quarters."
      },
      {
        "title": "Is Krystal Biotech, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-krystal-biotech-inc-overvalued-or-undervalued-3637786",
        "imagepath": "",
        "date": "2025-10-21 12:08:58",
        "description": "As of 17 October 2025, the valuation grade for Krystal Biotech, Inc. has moved from fair to very expensive, indicating that the stock is overvalued. The company exhibits a P/E ratio of 27, a Price to Book Value of 4.02, and an EV to EBITDA of 23.83, all of which suggest a premium valuation compared to its peers. For instance, BridgeBio Pharma, Inc. has a P/E ratio of -14.12, while Elanco Animal Health, Inc. shows a P/E of 19.25, highlighting Krystal's relatively high valuation.\n\nIn terms of recent performance, Krystal Biotech has outperformed the S&P 500, with a 3-year return of 177.42% compared to the S&P 500's 81.19%. This strong performance contrasts with its current valuation metrics, reinforcing the conclusion that the stock is overvalued...."
      },
      {
        "title": "Krystal Biotech Experiences Revision in Its Stock Evaluation Amid Strong Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/krystal-biotechs-valuation-grade-changes-from-fair-to-very-expensive-amid-price-increase-3641135",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/KrystalBiotechI_valuationdot_3641135.png",
        "date": "2025-10-20 17:28:46",
        "description": "Krystal Biotech, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 27 and a price-to-book value of 4.02. The company demonstrates strong financial metrics, including a ROCE of 36.18% and a year-to-date stock return of 21.43%, outperforming the S&P 500."
      },
      {
        "title": "Is Krystal Biotech, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-krystal-biotech-inc-overvalued-or-undervalued-3634658",
        "imagepath": "",
        "date": "2025-10-20 12:26:23",
        "description": "As of 17 October 2025, the valuation grade for Krystal Biotech, Inc. has moved from fair to very expensive. This suggests that the company is overvalued at its current price of $190.23. Key valuation ratios include a P/E ratio of 27, an EV to EBITDA of 23.83, and a Price to Book Value of 4.02, all indicating a premium compared to industry peers. For instance, BridgeBio Pharma, Inc. has a P/E of -14.12, while Elanco Animal Health, Inc. shows a P/E of 19.25, highlighting Krystal's elevated valuation.\n\nIn terms of performance, Krystal Biotech has outperformed the S&P 500 across multiple periods, with a 3-year return of 177.42% compared to the S&P 500's 81.19%. This strong performance, however, does not negate the fact that the stock is currently considered very expensive relative to its peers and valuation metrics...."
      },
      {
        "title": "Is Krystal Biotech, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-krystal-biotech-inc-overvalued-or-undervalued-3632195",
        "imagepath": "",
        "date": "2025-10-19 12:03:54",
        "description": "As of 17 October 2025, the valuation grade for Krystal Biotech, Inc. has moved from fair to very expensive, indicating a significant shift in its perceived value. The company appears overvalued based on its current metrics, including a P/E ratio of 27, a Price to Book Value of 4.02, and an EV to EBITDA ratio of 23.83. In comparison, peers such as Elanco Animal Health, Inc. have a P/E of 19.25, and Halozyme Therapeutics, Inc. has a fair valuation with a P/E of 15.92, highlighting Krystal's premium valuation relative to its industry.\n\nDespite the overvaluation, Krystal Biotech has shown strong performance in recent returns, with a year-to-date return of 21.43% compared to the S&P 500's 13.30%. This outperformance over multiple periods, including a remarkable 268.52% return over five years, suggests that investor sentiment may still support the stock despite its high valuation metrics...."
      },
      {
        "title": "Krystal Biotech Forms Golden Cross, Signaling Potential Bullish Breakout",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/krystal-biotech-forms-golden-cross-signaling-potential-bullish-breakout-3619690",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/KrystalBiotechI_goldencross_3619690.png",
        "date": "2025-10-14 15:31:48",
        "description": "Krystal Biotech, Inc. has recently achieved a Golden Cross, signaling potential upward momentum. The stock has outperformed the S&P 500 significantly over the past month and year-to-date, with positive technical indicators suggesting strong investor interest as it navigates the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 21,
    "sid": "1245865",
    "stock_news_url": "https://www.marketsmojo.com/news/krystal-biotech-inc-1245865"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Krystal Biotech Adjusts Valuation Amid Strong Financial Performance and Growth Indicators

2025-11-11 16:37:05

Krystal Biotech, Inc. has recently experienced a revision in its evaluation, moving to a fair valuation grade. The company showcases strong financial metrics, including a P/E ratio of 27 and a PEG ratio of 0.25, alongside impressive returns on capital and equity, reflecting effective resource management and consistent growth.

Is Krystal Biotech, Inc. overvalued or undervalued?

2025-11-11 11:33:51

As of 7 November 2025, the valuation grade for Krystal Biotech, Inc. moved from expensive to fair. This suggests that the stock is currently fairly valued. Key valuation ratios include a P/E ratio of 27, an EV to EBITDA ratio of 23.83, and a PEG ratio of 0.25, indicating a strong growth potential relative to its price. In comparison to its peers, Krystal Biotech's P/E ratio is higher than that of Halozyme Therapeutics, Inc., which has a P/E of 15.92, and significantly above Elanco Animal Health, Inc. at 19.25. Despite this, the company has demonstrated robust performance with a year-to-date return of 27.36%, significantly outpacing the S&P 500's return of 14.40% over the same period, reinforcing the notion that the stock is positioned well in the market....

Is Krystal Biotech, Inc. overvalued or undervalued?

2025-11-09 11:09:12

As of 7 November 2025, Krystal Biotech, Inc. has moved from an expensive to a fair valuation grade. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 27, a Price to Book Value of 4.02, and an EV to EBITDA ratio of 23.83. In comparison to its peers, Krystal's P/E ratio is higher than Halozyme Therapeutics, Inc. at 15.92 and Elanco Animal Health, Inc. at 19.25, indicating a premium valuation relative to these companies. The PEG ratio of 0.25 suggests that the stock may be undervalued in terms of its growth prospects, especially when compared to the industry average. Additionally, Krystal Biotech has delivered strong returns, outperforming the S&P 500 with a year-to-date return of 26.34% compared to the index's 14.40%. Overall, the valuation metrics and strong performance suggest that Krystal Biotech is fairly valued at this time....

Krystal Biotech Hits New 52-Week High of $212.98, Showcasing Strong Growth

2025-11-05 16:51:53

Krystal Biotech, Inc. has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. The company has a market capitalization of USD 4,203 million, a P/E ratio of 27.00, and has reported significant growth in net profit and operating cash flow over recent quarters.

Is Krystal Biotech, Inc. overvalued or undervalued?

2025-10-21 12:08:58

As of 17 October 2025, the valuation grade for Krystal Biotech, Inc. has moved from fair to very expensive, indicating that the stock is overvalued. The company exhibits a P/E ratio of 27, a Price to Book Value of 4.02, and an EV to EBITDA of 23.83, all of which suggest a premium valuation compared to its peers. For instance, BridgeBio Pharma, Inc. has a P/E ratio of -14.12, while Elanco Animal Health, Inc. shows a P/E of 19.25, highlighting Krystal's relatively high valuation. In terms of recent performance, Krystal Biotech has outperformed the S&P 500, with a 3-year return of 177.42% compared to the S&P 500's 81.19%. This strong performance contrasts with its current valuation metrics, reinforcing the conclusion that the stock is overvalued....

Krystal Biotech Experiences Revision in Its Stock Evaluation Amid Strong Market Performance

2025-10-20 17:28:46

Krystal Biotech, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 27 and a price-to-book value of 4.02. The company demonstrates strong financial metrics, including a ROCE of 36.18% and a year-to-date stock return of 21.43%, outperforming the S&P 500.

Is Krystal Biotech, Inc. overvalued or undervalued?

2025-10-20 12:26:23

As of 17 October 2025, the valuation grade for Krystal Biotech, Inc. has moved from fair to very expensive. This suggests that the company is overvalued at its current price of $190.23. Key valuation ratios include a P/E ratio of 27, an EV to EBITDA of 23.83, and a Price to Book Value of 4.02, all indicating a premium compared to industry peers. For instance, BridgeBio Pharma, Inc. has a P/E of -14.12, while Elanco Animal Health, Inc. shows a P/E of 19.25, highlighting Krystal's elevated valuation. In terms of performance, Krystal Biotech has outperformed the S&P 500 across multiple periods, with a 3-year return of 177.42% compared to the S&P 500's 81.19%. This strong performance, however, does not negate the fact that the stock is currently considered very expensive relative to its peers and valuation metrics....

Is Krystal Biotech, Inc. overvalued or undervalued?

2025-10-19 12:03:54

As of 17 October 2025, the valuation grade for Krystal Biotech, Inc. has moved from fair to very expensive, indicating a significant shift in its perceived value. The company appears overvalued based on its current metrics, including a P/E ratio of 27, a Price to Book Value of 4.02, and an EV to EBITDA ratio of 23.83. In comparison, peers such as Elanco Animal Health, Inc. have a P/E of 19.25, and Halozyme Therapeutics, Inc. has a fair valuation with a P/E of 15.92, highlighting Krystal's premium valuation relative to its industry. Despite the overvaluation, Krystal Biotech has shown strong performance in recent returns, with a year-to-date return of 21.43% compared to the S&P 500's 13.30%. This outperformance over multiple periods, including a remarkable 268.52% return over five years, suggests that investor sentiment may still support the stock despite its high valuation metrics....

Krystal Biotech Forms Golden Cross, Signaling Potential Bullish Breakout

2025-10-14 15:31:48

Krystal Biotech, Inc. has recently achieved a Golden Cross, signaling potential upward momentum. The stock has outperformed the S&P 500 significantly over the past month and year-to-date, with positive technical indicators suggesting strong investor interest as it navigates the Pharmaceuticals & Biotechnology sector.

View All News